COVID-19 Advanced Care

Fouka, Evangelia; Kalomenidis, Ioannis; Gianniou, Niki; Gida, Sofia; Steiropoulos, Paschalis

doi:10.3390/jpm11111082

Cited by 2 publications

(2 citation statements)

References 87 publications

(102 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…В исследовании в Ухане, в котором сообщалось о результатах лечения 191 пациента, госпитализированного с COVID-19, 50 % смертей были связаны с вторичными бактериальными инфекциями [36]. При этом наиболее распространёнными классами назначаемых антибиотиков являются фторхинолоны, за которыми следуют макролиды и цефалоспорины [37,38]. В ретроспективном исследовании Tsay SV и соавт., 346 204 (29,6 %) из 1 169 120 амбулаторных посещений пациентов с COVID-19 были связаны с назначением антибиотиков.…”

Section: компьютерная томография (ктunclassified

Factors associated with adverse outcome among hospitalized patients with moderate to severe COVID-19

Mishinova

Gomon

Kolbin

et al. 2023

GCP

View full text Add to dashboard Cite

Aims. To consider factors associated with adverse outcome among hospitalized patients with moderate and severe COVID-19.Materials and methods. Data from 345 case histories of adult patients hospitalized with moderate to severe COVID-19 were analyzed in a single-center retrospective study. Characteristics by sex, age, number of days from disease onset to admission to hospital, duration of hospitalization, duration of disease, population characteristics by medical history of comorbidities and self-medication, outcome of hospitalization and medical technologies used in hospital conditions were given for the whole cohort of patients. All parameters were analyzed using descriptive statistics methods. Qualitative variables are given in absolute (n) and relative (%) values with 95% confidence interval. Continuous variables were presented as median and quartiles. Risk factors for mortality were determined across groups using the χ2 criterion and odds ratio.Results. There was no demonstrated effect of gender, degree of pulmonary tissue lesions on computed tomography data, or time of initiation of respiratory support on disease outcome. At the same time, the age older than 65 years as well as neoplasms, type 2 diabetes mellitus, dementia, Stage 3 arterial hypertension, chronic heart failure, coronary heart disease, myocardial infarction and stroke history, chronic obstructive pulmonary disease, bronchiectatic disease, urogenital diseases were the predictors of unfavorable outcome in patients with moderate and severe COVID-19 form. Prehospital use of antiplatelet agents, direct and indirect oral anticoagulants, drugs affecting the renin-angiotensin system, systemic glucocorticosteroids, antibiotics, antiviral drugs, and analgesics was associated with a decrease in the mortality rate in patients with moderate-to-severe COVID-19, as well as timely use of pronposition and transfer to intensive care unit.Conclusions. Our findings are partially consistent with previous reports on the effect of risk factors on COVID-19 outcomes.

show abstract

Section: компьютерная томография (ктunclassified

Factors associated with adverse outcome among hospitalized patients with moderate to severe COVID-19

Mishinova

Gomon

Kolbin

et al. 2023

GCP

View full text Add to dashboard Cite

show abstract

“…The COVID-19 outbreak is the result of uncommon intensive acute respiratory syndrome coronavirus 2 (SARS-CoV-2), which has caused a global unexpected and major increase in hospital admissions for treatment of lung and other organ infections like the digestive organs [1,2]. In mid-November 2002, Covid-19 was identified as SARS for the first time in China and early in 2003, the World Health Organization became aware of the disease and it continued until 2003, spreading around the world, affecting 24 countries in Asia including Cambodia, Hong Kong, Singapore, Hanoi and Canada in North America, and other countries to a lesser extent, causing 8,437 SARS cases and 813 deaths [3].…”

Section: Covid-19 Diseasementioning

confidence: 99%

Effect of Covid-19 Vaccine on Women's Fertility Hormones

Najeb¹,

Mohammed²,

Rasheed³

2022

View full text Add to dashboard Cite

The coronavirus disease 2019 (COVID-19), as a result of the modern intense respiratory syndrome coronavirus 2, caused an unexpected fundamental global raise in the admission to hospitals for lung and other organ diseases. COVID-19 vaccination has increased and accelerated in a conscionable progress. More than 184 nominee vaccines are being tested in preclinical use and 104 in clinical stages of development. The current study aimed to know the impact of the COVID-19 vaccine on female fertility hormones. The results obtained from the current study showed a slight increase in FSH and LH hormones for women infected with Covid-19 virus and for women who received the vaccine to prevent covid-19 virus compared to healthy, uninfected and unvaccinated groups (FSH 10.26±3.86 ,15.32±2.04 LH 15.41±2.76, 10.40±1.58 respectively), with non-significant differences (P>0.05), while the prolactin hormone levels showed a highly significant increase (P<0.01) in infected women who took the vaccine in comparison with its levels in healthy women who did not receive the vaccine and not infected (32.32±6.48, 19.62±4.04, 10.27±6.88 respectively). Conclusions: Covid- 19 vaccine affected the female hormones in one way or another.

show abstract

COVID-19 Advanced Care

Cited by 2 publications

References 87 publications

Factors associated with adverse outcome among hospitalized patients with moderate to severe COVID-19

Factors associated with adverse outcome among hospitalized patients with moderate to severe COVID-19

Effect of Covid-19 Vaccine on Women's Fertility Hormones

Contact Info

Product

Resources

About